INDV
Indivior Pharmaceuticals Inc
$40.93
+0.70
(+1.74%)
Mkt Cap
5.11B
Volume
1,844,327
52W Range
15-42.81
Sector
Healthcare
Beta
1.15
EPS (TTM)
2.01
P/E Ratio
20.36
Revenue (TTM)
1.29B
Rev Growth (5Y)
+13.9%
EPS Growth (5Y)
+25.3%
AlphaVal · Fair Value
What we estimate one share is worth
$29.73
Overvalued
moderate signal
37.7% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.19B | 1.09B | 901.00M | 791.00M | 647.00M | 785.00M | 959.92M | 1.15B | 968.89M |
| Net Income | 210.00M | 2.00M | (129.00M) | (44.00M) | 205.00M | (148.00M) | 134.00M | 262.67M | 60.92M | 32.05M |
| EPS | 1.68 | 0.02 | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| Free Cash Flow | (93.00M) | 7.00M | (353.00M) | (9.00M) | 319.00M | (197.00M) | 144.00M | 250.25M | 264.70M | 340.67M |
| FCF / Share | -0.74 | 0.05 | -2.57 | -0.06 | 2.19 | -1.34 | 0.99 | 1.72 | 1.84 | 2.37 |
| Operating CF | (27.00M) | 36.00M | (300.00M) | (4.00M) | 353.00M | (193.00M) | 151.00M | 289.41M | 309.87M | 372.72M |
| Total Assets | 1.20B | 1.32B | 1.76B | 1.78B | 1.83B | 1.53B | 1.65B | 1.55B | 1.44B | 1.21B |
| Total Debt | 351.00M | 375.00M | 283.00M | 277.00M | 286.00M | 285.00M | 293.00M | 241.00M | 482.00M | 535.00M |
| Cash & Equiv | 195.00M | 319.00M | 316.00M | 778.18M | 1.10B | 858.00M | 1.06B | 924.00M | 863.00M | 692.00M |
| Book Value | (98.00M) | (348.00M) | (191.00M) | 51.28M | 203.00M | 82.00M | 209.00M | 66.00M | (203.00M) | (295.00M) |
| Return on Equity | N/A | N/A | N/A | -0.86 | 1.01 | -1.80 | 0.64 | 3.98 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 317.00M | 358.00M | 314.00M | 302.00M | 266.00M | 299.00M | 307.00M | 299.00M | 284.00M | 293.00M | 271.00M | 276.00M |
| Net Income | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M | 59.00M | 4.00M | (97.00M) | 61.00M | 54.00M | (135.00M) | 39.00M |
| EPS | 0.71 | 0.82 | 0.34 | 0.14 | 0.38 | 0.45 | 0.03 | -0.72 | 0.45 | 0.39 | -0.94 | 0.29 |
| Free Cash Flow | (29.00M) | (245.00M) | (59.00M) | 148.38M | 70.00M | (21.49M) | (1.00M) | 83.83M | (56.75M) | (283.62M) | 19.12M | (20.86M) |
| FCF / Share | -0.23 | -1.96 | -0.47 | 1.20 | 0.57 | -0.17 | -0.01 | 0.62 | -0.42 | -2.07 | 0.14 | -0.15 |
| Operating CF | (9.00M) | (221.00M) | (39.00M) | 166.04M | 75.00M | (5.65M) | 8.00M | 87.83M | (54.76M) | (279.72M) | 21.17M | (19.83M) |
| Total Assets | 1.20B | 1.20B | 1.42B | 1.45B | 1.38B | 1.32B | 1.46B | 1.54B | 1.45B | 1.76B | 1.85B | 1.73B |
| Total Debt | 509.00M | 351.00M | 356.00M | 366.00M | 370.00M | 375.00M | 284.00M | 281.04M | 278.79M | 283.00M | 277.00M | 281.00M |
| Cash & Equiv | 175.00M | 195.00M | 445.00M | 510.00M | 372.00M | 319.00M | 288.00M | 302.05M | 247.81M | 316.00M | 610.00M | 592.00M |
| Book Value | (144.00M) | (98.00M) | (207.00M) | (258.00M) | (286.00M) | (348.00M) | (167.00M) | (121.02M) | 9.99M | (191.00M) | (24.00M) | 117.00M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 6.10 | N/A | N/A | 0.33 |
INDV News
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
INDV Stock: What Sublocade Growth Signals for 2026
Is Indivior Stock a Buy After Higher 2026 Guidance?
5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics
What to Know About This Fund's $74.8 Million Indivior Sale
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%